Abstract 1777P
Background
Effective therapy in pediatric-type sarcomas for adult patients remains an unmet need, with older age being a poor prognostic factor. NGS can identify potential therapeutic targets and characterize the tumor microenvironment (TME) in these patients.
Methods
Whole-exome and whole-transcriptome NGS were performed on samples from 16 patients aged 4–62 years with pediatric-type fusion-driven sarcoma (PTFDS: Ewing sarcoma - EwS, alveolar rhabdomyosarcoma - AlvR) to identify potentially targetable molecular events and classify samples into TME subtypes. The frequency of targetable events was compared between younger and older patients; the selected cutoff of 30 years is a common age limit in disease-specific clinical trials.
Results
Detected genetic events included EWSR1-FLI1 (n = 9), PAX3-FOXO1 (n = 5), and EWSR1-ETV4 (n = 1) fusions; RB1 (n = 1) and PTEN (n = 1) losses; somatic and germline CDKN2A (n = 2) mutations, somatic TP53 (n = 2), PIK3CA (n = 1), ATM (n = 1) and germline BRCA1 (n = 1) mutations; FGFR4 (n = 2), MYC (n = 1), and EZH2 (n = 1) amplifications. We hypothesized that worse outcomes in older PTFDS patients could be associated with increased frequency of additional targetable driver events. We compared the frequency of targetable genetic events between younger (4-28 years, median = 23) and older (32-62 years, median = 40) patients with EwS and AlvR. Targetable events were more common in older (71%, 5/7) compared to younger patients (22%, 2/9), albeit the sample size was too small to reach statistical significance. Transcriptomic-based TME profiling showed that 94% (n =15) of patients had Fibrotic/Immune Desert subtypes associated with a predicted poor response to immune checkpoint inhibitors (ICI). One EwS patient had an Immune-Enriched subtype associated with predicted benefit from ICI. The distribution of TME subtypes within sarcoma types conforms well with previously reported lack of response to ICI in PTFDS patients.
Conclusions
Comprehensive molecular profiling revealed targetable events that may benefit older patients with PTFDS by expanding potential therapeutic options and inclusion in biomarker-driven trials without strict age limits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BostonGene, Corp.
Disclosure
A.P. Conley: Financial Interests, Personal, Research Funding: Eli Lilly, EpicentRx, Kronos Bio, Krystal Biotech, Inhbrx, NCI, Roche; Financial Interests, Personal, Research Grant: Chordoma Foundation; Financial Interests, Personal, Speaker, Consultant, Advisor: Aadi Biosciences, Guide Point. A. Aukhadieva, I. Zhuk, M. Voropaeva: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Novokreshchenova: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp. A.E. Shevkoplias: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. K. Zirov: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Makarova: Financial Interests, Personal, Financially compensated role: BostonGene, Corp. A. Dubrovskaya: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Nadiryan: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Financially compensated role, employee: BostonGene, Corp. L. Balabanian: Financial Interests, Personal, Financially compensated role, employee: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Bagaev: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.; Financial Interests, Personal, Proprietary Information: BostonGene, Corp. E. Choy: Financial Interests, Personal, Advisory Board: Sonata Therapeutics, Adaptimmune; Financial Interests, Personal, Research Funding: Adaptimmune, Amgen, AstraZeneca, Bayer, Exelixis, GSK, Iterion, Novartis, Merck, Mirati. R. Ratan: Financial Interests, Personal, Advisory Board: SpringWorks, Ipsen; Financial Interests, Personal, Advisory Role: Inhibrx; Financial Interests, Personal, Coordinating PI: Ayala, C4 Therapeutics, SpringWorks; Financial Interests, Personal, Research Funding: SpringWorks, C4 Therapeutics, Ayala; Financial Interests, Personal, Speaker, Consultant, Advisor, Invited Speaker: SpringWorks. L. Bednyagin: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp. S.P. Chawla: Financial Interests, Personal, Stocks/Shares, Own stocks.: Cellestia pharma; Financial Interests, Personal, Stocks/Shares, Stocks: Adi Biopharma; Financial Interests, Personal, Ownership Interest, Owner and stocks: Counterpoint; Financial Interests, Institutional, Local PI, Clinical research: Amgen; Financial Interests, Institutional, Local PI, Research: Adi bio, NK Gene, BMS, Rain Therapeutic, Shasqui, Monopar, Ayala, Boeinger; Financial Interests, Personal, Local PI, Research: Rain Therapeutic, Molleculin.
Resources from the same session
1393TiP - A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nicolas Girard
Session: Poster session 06
1394TiP - KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Presenter: Marina Garassino
Session: Poster session 06
1395TiP - A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Presenter: Antonio Passaro
Session: Poster session 06
1397TiP - Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Presenter: Stephen Liu
Session: Poster session 06
Resources:
Abstract
1398TiP - Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Presenter: Solange Peters
Session: Poster session 06
1399TiP - Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial)
Presenter: Danielli Matias
Session: Poster session 06
1728P - Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Presenter: Sant Chawla
Session: Poster session 06
1729P - Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Presenter: Anmol Dia Agarwal
Session: Poster session 06